Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease
- PMID: 18413473
- PMCID: PMC2723757
- DOI: 10.1001/archneur.65.4.499
Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease
Abstract
Background: A majority of mutations within the beta-amyloid region of the amyloid precursor protein (APP) gene cause inherited forms of intracerebral hemorrhage. Most of these mutations may also cause cognitive impairment, but the Arctic APP mutation is the only known intra-beta-amyloid mutation to date causing the more typical clinical picture of Alzheimer disease.
Objective: To describe features of 1 Swedish and 1 American family with the previously reported Arctic APP mutation.
Design, setting, and participants: Affected and nonaffected carriers of the Arctic APP mutation from the Swedish and American families were investigated clinically. In addition, 1 brain from each family was investigated neuropathologically.
Results: The clinical picture, with age at disease onset in the sixth to seventh decade of life and dysfunction in multiple cognitive areas, is indicative of Alzheimer disease and similar to the phenotype for other Alzheimer disease APP mutations. Several affected mutation carriers displayed general brain atrophy and reduced blood flow of the parietal lobe as demonstrated by magnetic resonance imaging and single-photon emission computed tomography. One Swedish case and 1 American case with the Arctic APP mutation came to autopsy, and both showed no signs of hemorrhage but revealed severe congophilic angiopathy, region-specific neurofibrillary tangle pathological findings, and abundant amyloid plaques. Intriguingly, most plaques from both of these cases had a characteristic ringlike character.
Conclusions: Overall, our findings corroborate that the Arctic APP mutation causes a clinical and neuropathological picture compatible with Alzheimer disease.
Figures




Similar articles
-
Alzheimer's disease families with amyloid precursor protein mutations.Ann N Y Acad Sci. 1993 Sep 24;695:198-202. doi: 10.1111/j.1749-6632.1993.tb23052.x. Ann N Y Acad Sci. 1993. PMID: 8239283 Review.
-
A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation.Dement Geriatr Cogn Disord. 1999 Nov-Dec;10(6):526-33. doi: 10.1159/000017200. Dement Geriatr Cogn Disord. 1999. PMID: 10559570 Clinical Trial.
-
Brain volumes and regional cerebral blood flow in carriers of the Swedish Alzheimer amyloid protein mutation.Alzheimer Dis Assoc Disord. 1998 Mar;12(1):49-53. doi: 10.1097/00002093-199803000-00008. Alzheimer Dis Assoc Disord. 1998. PMID: 9539411
-
Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val-->Ile mutation in the amyloid precursor protein gene.Neurobiol Aging. 1993 Sep-Oct;14(5):407-19. doi: 10.1016/0197-4580(93)90099-w. Neurobiol Aging. 1993. PMID: 8247223
-
Findings from the Swedish Study on Familial Alzheimer's Disease Including the APP Swedish Double Mutation.J Alzheimers Dis. 2018;64(s1):S491-S496. doi: 10.3233/JAD-179922. J Alzheimers Dis. 2018. PMID: 29614673 Review.
Cited by
-
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.Alzheimers Res Ther. 2011 Jan 6;3(1):1. doi: 10.1186/alzrt59. Alzheimers Res Ther. 2011. PMID: 21211070 Free PMC article.
-
The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ.Acta Neuropathol Commun. 2013 Sep 10;1:60. doi: 10.1186/2051-5960-1-60. Acta Neuropathol Commun. 2013. PMID: 24252272 Free PMC article.
-
In vivo Evaluation of a Newly Synthesized Acetylcholinesterase Inhibitor in a Transgenic Drosophila Model of Alzheimer's Disease.Front Neurosci. 2021 Jun 30;15:691222. doi: 10.3389/fnins.2021.691222. eCollection 2021. Front Neurosci. 2021. PMID: 34276297 Free PMC article.
-
Differential effects of familial Alzheimer's disease-causing mutations on amyloid precursor protein (APP) trafficking, proteolytic conversion, and synaptogenic activity.Acta Neuropathol Commun. 2023 Jun 1;11(1):87. doi: 10.1186/s40478-023-01577-y. Acta Neuropathol Commun. 2023. PMID: 37259128 Free PMC article.
-
Blood-Brain Barrier: From Physiology to Disease and Back.Physiol Rev. 2019 Jan 1;99(1):21-78. doi: 10.1152/physrev.00050.2017. Physiol Rev. 2019. PMID: 30280653 Free PMC article. Review.
References
-
- Chartier-Harlin MC, Crawfort F, Houlden H, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature. 1991;353:844–846. - PubMed
-
- Murrell J, Farlow M, Ghetti B, Benson MD. A mutation in the amyloid precursor protein gene associated with hereditary Alzheimer's disease. Science. 1991;254:97–99. - PubMed
-
- Mullan M, Crawford F, Axelman K, et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet. 1992;1:345–7. - PubMed
-
- Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754–760. - PubMed
-
- Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron. 1996;17:1005–13. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical